Drug intelligence / Profile preview

BNT317

Development stage: Phase 2
Lead developer: BioNTech

Overview

BNT317 is an investigational therapy developed by BioNTech for the treatment of advanced solid tumors. It is currently being evaluated in a first-in-human, open-label, multi-site, dose escalation Phase 1 clinical trial to assess its safety, tolerability, pharmacokinetics (PK), and immunogenicity in adult patients with advanced solid tumors who have failed standard therapies or for whom no standard treatment options are available. The specific mechanism of action and molecular modality of BNT317 have not been publicly disclosed as of June 2025[1][2][3][7][9].

Targets

CD274 (Programmed cell death protein 1 ligand 1)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on BNT317.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BNT317.

Explore the full profile